Regeneron Pharmaceuticals today announced financial results for the fourth quarter and full year 2024 and provided a business ...

Johnson & Johnson (NYSE: JNJ) has gone big early doors this year in the world of pharma M&A. The US healthcare giant ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

We recently published a list of 10 Best Stocks to Buy and Hold For 2025. In this article, we are going to take a look at ...

Pharmaceuticals, a leading biotechnology company with a market capitalization of $73.94 billion, finds itself at a critical juncture as it navigates challenges to its flagship Eylea franchise while ...

Regeneron (NASDAQ:REGN ... data to be sufficient to address FDA concerns from an initial Complete Response Letter (CRL). If approved, Dupixent could add an estimated $340 million in revenue ...

Regeneron recently announced that the primary ... The regulatory body issued complete response letters (CRL) for its biologics license application (BLA) for odronextamab in March 2024.

CNN is cutting hundreds of TV jobs in a digital pivot. Read the memo CEO Mark Thompson sent to staff. 25 Days Building The Most Amazing House Under The hill in forest ...

Regulatory setbacks, including the FDA’s complete response letter for linvoseltamab, further contributed to investor concerns. Analysts' consensus rating on Regeneron Pharmaceuticals stock is ...

Learn more about whether Ultragenyx Pharmaceutical Inc. or Vericel Corporation is a better investment based on AAII's A+ ...

EyePoint's Duravyu, a potential "best-in-class" therapy for Wet AMD and DME, could disrupt the market with fewer injections ...

When the FDA turned down odronextamab in a complete response letter in March, Regeneron said that it was because it had not yet started trials that would be used to confirm accelerated approvals ...